AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Vitrafy Life Sciences Limited (ASX:VFY) has successfully applied for quotation of 41,667 ordinary fully paid shares following the exercise of options expiring on 30 June 2029, at an exercise price of $1.42 per share. This share issuance was completed on 22 July 2026, increasing the company’s quoted capital base. The conversion of these convertible securities into ordinary equity expands Vitrafy’s issued capital structure.
Key Highlights
- Vitrafy Life Sciences Limited (VFY) seeks quotation for 41,667 ordinary fully paid shares issued on 22 July 2026
- Shares issued after exercising options expiring 30 June 2029 with a $1.42 exercise price
- Total quoted ordinary fully paid shares will reach 62,336,675 after this issuance
- Company holds approximately 19.9 million unquoted securities, including options and performance rights
Option Exercise at $1.42 Strike Price Triggers Share Issuance
Vitrafy Life Sciences Limited has completed the exercise of options under ASX code VFYAJ, which expire on 30 June 2029 and carry an exercise price of $1.42 per share. The company has applied for quotation of the 41,667 ordinary fully paid shares issued on 22 July 2026 as a result of this conversion. This corporate action reflects option holders’ decision to convert their derivative holdings into ordinary equity at the predetermined strike price.
The $1.42 exercise price represents the economic value at which option holders deemed conversion beneficial. Per ASX Listing Rules, these newly issued shares rank equally with existing ordinary shares in all respects from their issue date. The company has not disclosed the identities of the option holders or the original grant dates. This transaction highlights ongoing engagement with Vitrafy’s capital structure by existing security holders.
Issued Capital Expanded Following Option Conversion
Post-quotation of the 41,667 new shares, Vitrafy Life Sciences’ total quoted ordinary fully paid share capital will be 62,336,675 shares. Although the company has not specified the prior share count, this issuance reflects a typical capital management event converting options into equity, allowing investors to increase their direct ownership.
Beyond quoted shares, Vitrafy holds a significant portfolio of unquoted securities totaling approximately 19.9 million instruments. These include 996,667 options with various expiry dates and exercise prices, 673,431 performance rights, 13,903,936 restricted ordinary fully paid shares, and multiple tranches of restricted options. This diversified unquoted securities portfolio indicates a structured capital and incentive framework targeting management, employees, and stakeholders.
Outstanding Options Remain After Partial Exercise
Following the exercise, 50,000 VFYAJ options (expiring 30 June 2029 at $1.42) remain unexercised, indicating only a portion of this option class was converted on 22 July 2026. The company has not provided details on the timing or likelihood of exercising these remaining options or the holders’ intentions. This suggests option holders may be assessing market conditions before exercising all rights.
Additionally, Vitrafy maintains other option tranches with varying expiry dates and strike prices, including 99,320 options expiring 29 June 2027 at $4.00 per share, and other options totaling 996,667. The variety of expiry dates and strike prices reflects multiple capital raises or employee incentive plans executed over time, aligned with prevailing market conditions at grant.
Restricted Shares and Performance Rights Held Unquoted
The company holds 13,903,936 restricted ordinary fully paid shares, which are subject to transfer or sale restrictions for specified periods, typically to retain founders, employees, or early investors. Specific restriction terms and holders have not been disclosed. These restricted shares help incentivize long-term commitment while managing market impact from large share releases.
Vitrafy also has 673,431 unquoted performance rights under ASX code VFYAL. These rights vest upon achieving defined company milestones or performance targets, aligning compensation with strategic goals. Details on vesting schedules or beneficiaries have not been provided. The combination of restricted shares and performance rights demonstrates a sophisticated equity-based compensation and retention strategy.
Capital Structure and Potential Shareholder Dilution
Including both quoted and unquoted securities, Vitrafy’s total instruments outstanding approximate 82.2 million. Quoted ordinary shares total 62,336,675, while unquoted securities account for roughly 19.9 million. This layered capital structure provides flexibility but also introduces potential dilution as options are exercised, performance rights vest, and restricted shares become unrestricted.
The 41,667 shares issued represent about 0.067% dilution of the post-exercise ordinary share capital, a modest impact for current shareholders. However, the larger pool of unexercised options and unvested performance rights poses a more significant future dilution risk. The eventual unrestricted status of the 13.9 million restricted shares may also influence market dynamics depending on timing and holder sentiment. Investors should monitor market conditions and company disclosures for updates on dilution timing and magnitude.
ASX Quotation and Compliance Procedures
Vitrafy filed an Appendix 2A with the Australian Securities Exchange to apply for official quotation of the 41,667 newly issued shares. This is the standard ASX process for notifying security issuances resulting from option exercises or convertible security conversions. The application confirms these shares carry equal rights, including voting and dividends, as existing quoted ordinary shares from the issue date.
No unusual terms or conditions were disclosed for the new shares, and no delays in quotation approval were indicated. The $1.42 exercise price was paid in Australian dollars. Compliance with ASX Listing Rules requires timely notification of all security movements to avoid regulatory sanctions or suspension. This filing demonstrates Vitrafy’s adherence to continuous disclosure obligations.
Capital Management Strategy and Future Outlook
The exercise of options at the $1.42 strike price is part of Vitrafy Life Sciences’ broader capital management and equity strategy. Maintaining multiple tranches of options, performance rights, and restricted shares allows the company to manage dilution, retain key personnel, and align stakeholder incentives with corporate performance. Partial exercise of VFYAJ options suggests market conditions or holder preferences influenced conversion decisions.
The company has not provided guidance on future option exercises, share issuances, or capital plans. Investors should watch for updates on remaining option exercises, performance rights vesting, and restricted share unrestriction schedules. Material corporate actions such as capital raises or acquisitions could prompt further share or option issuances, affecting the capital structure. Vitrafy’s management of its complex securities portfolio will be critical to long-term shareholder value and funding growth initiatives.
Important Dates and Investor Considerations
The option exercise and share issuance occurred on 22 July 2026. The remaining 50,000 VFYAJ options expire on 30 June 2029, giving holders approximately three years to exercise. Other option classes have staggered expiry dates: VFYAG and VFYAI options expire on 29 June 2027, and VFYAH options expire on 30 June 2029.
This staggered expiry schedule reflects multiple capital raises and incentive programs implemented over recent years, creating a rolling timeline of potential capital management events. Investors should monitor quarterly and annual reports for disclosures on option portfolio changes, early exercises, or amendments. The next key milestones will be the natural expirations of these options unless extensions or modifications are announced.
